Figure 1.
P16 was downregulated in luminal-A of DCIS but upregulated in triple-negative breast cancer.
Typical images of p16 IHC staining are shown at two different magnifications: top, 100×; bottom, 400× for the boxed areas of the top images.
Figure 2.
Triple-negative breast cancer samples were negative for p53 mutation.
Typical images of p53 IHC staining are shown at two different magnifications: top, 100×; bottom, 400× for the boxed areas of the top images.
Table 1.
P16 expression in different breast cancer subtypes.
Table 2.
Correlation between breast cancer clinical factors and p16 expression in DCIS and IDC.
Figure 3.
P16 expression predicted the risk of subsequent advanced cancer development among women with luminal DCIS.
P = 0.001, low-p16-expression DCIS versus high-p16-expression DCIS (log-rank test).
Table 3.
P16 pathways of different groups correlated to the p53 pathway.